Ferring Pharmaceuticals, Inc.
400 Rella Boulevard
47 articles with Ferring Pharmaceuticals, Inc.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
FDA Approves New Indications for ZOMACTON® (somatropin) as Ferring Plans Launch of Needle-Free Delivery System
Ferring Pharmaceuticals, Inc.. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications:
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
Male Fertility Survey Reveals 80 Percent of Men Feel Overlooked When Experiencing Infertility Challenges
Ferring Pharmaceuticals Inc. (US) has announced findings from a survey conducted with RESOLVE: The National Infertility Association to better understand how men feel when struggling with their own or their partner’s infertility.
Ferring to Present Clinical Data on Efficacy and Safety of CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep at Digestive Disease Week
Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present "A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety of a New Ready-to-Drink Low Volume Bowel Preparation Prior to Colonoscopy" (Poster # Tu2010)
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide
Agreement to Target New Oral Peptide Development Opportunity, Extending Successful Relationship between Enteris and Ferring
Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage
The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin vs. oxytocin, the current standard of care, for preventing PPH after vaginal birth
Ferring announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.
Ferring's CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Now Available
Colorectal cancer is the third most common cancer and second leading cause of cancer death in the United States.
Ferring's ZOMACTON (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Defic...
2/1/2018Ferring today announced that the FDA has approved ZOMACTON for Injection 5 mg and 10 mg recombinant human growth hormone indicated for replacement of GH in adults with GH deficiency.
Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.
Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.